Search Within

Jaclyn Frances Hechtman

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (65)
  2. Journal Article (63)
  3. Review (2)
  4. Book Section (1)
  5. Guidelines (1)
  6. Research Letter (1)
Groups
  1. GSK Faculty (133)
  2. Human Oncology and Pathogenesis Program (133)
  3. Department of Pathology and Laboratory Medicine (125)
  4. Department of Medicine (112)
  5. Solid Tumor Oncology Division (112)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (90)

More Groups

People
  1. Marc Ladanyi (69)
  2. Michael Berger (66)
  3. David Solit (52)
  4. Ahmet Zehir (50)
  5. Nikolaus Schultz (47)
  6. Jinru Shia (46)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (3)
  4. 2022 (1)
  5. 2021 (10)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Modern Pathology (16)
  3. Clinical Cancer Research (12)
  4. Laboratory Investigation (11)
  5. Journal of Molecular Diagnostics (10)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (34)
  2. American Association for Cancer Research (25)
  3. Nature Publishing Group (17)
  4. Nature Research (16)
  5. Elsevier Science, Inc. (11)
  6. Oxford University Press (8)

More Publishers

Results (133)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
    Meeting Abstract

    Cocco, E.; Kulick, A.; Misale, S.; Yaeger, R.; Razavi, P.; Won, H. H.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; Cownie, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Dissecting the role of zygosity and lineage in Lynch syndrome-associated microsatellite instability
    Meeting Abstract

    Srinivasan, P.; Bandlamudi, C.; Shia, J.; Latham, A. S.; Jonsson, P.; Penson, A.; Middha, S.; Hechtman, J.; Zehir, A.; Richards, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
    Journal Article

    Greally, M.; Chou, J. F.; Chatila, W. K.; Margolis, M.; Capanu, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Daian, F.; Ladanyi, M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
    Guidelines

    Marchiò, C.; Scaltriti, M.; Ladanyi, M.; Iafrate, A. J.; Bibeau, F.; Dietel, M.; Hechtman, J. F.; Troiani, T.; López-Rios, F.; Douillard, J. Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • NTRK fusion detection across three assays and 29,000 tumors
    Meeting Abstract

    Solomon, J.; Sireci, N.; Drilon, A.; Mullaney, K.; Benayed, R.; Ladanyi, M.; Hechtman, J.
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • NTRK fusion detection across three assays and 29,000 tumors
    Meeting Abstract

    Solomon, J.; Sireci, N.; Drilon, A.; Mullaney, K.; Benayed, R.; Ladanyi, M.; Hechtman, J.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer
    Journal Article

    Won, E.; Basunia, A.; Chatila, W. K.; Hechtman, J. F.; Chou, J. F.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high
    Journal Article

    Middha, S.; Yaeger, R.; Shia, J.; Stadler, Z. K.; King, S.; Guercio, S.; Paroder, V.; Bates, D. D. B.; Rana, S.; Diaz, L. A. Jr; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save